Fidanacogene Elaparvovec for Hemophilia B - A Multiyear Follow-up Study
{{output}}
Background: Treatment with fidanacogene elaparvovec, a recombinant adeno-associated virus (AAV) vector developed for the treatment of hemophilia B, led to sustained expression of the high-activity factor IX variant (FIX-R338L, or... ...
